Join the Depression group to help and get support from people like you.
Depression News (Page 27)
Related terms: Major Depression, Unipolar Depression
FDA Approves Spravato (esketamine) Nasal Spray for Treatment-Resistant Depression
March 5, 2019 – The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have...
FDA Approves Latuda (lurasidone HCl) for Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- March 6, 2018 – Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug...
FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
November 13, 2017 – The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an...
Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion
Deerfield, Ill., and Osaka, Japan (May 2, 2016) – Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) (collectively “Takeda”), and Lundb...
FDA Medwatch Alert: Brintellix (vortioxetine): Drug Safety Communication - Brand Name Change to Trintellix, to Avoid Confusion With Antiplatelet Drug Brilinta (ticagrelor)
ISSUE: FDA has approved a brand name change for the antidepressant Brintellix (vortioxetine) to decrease the risk of prescribing and dispensing errors resulting from name confusion with the ...
FDA Approves Rexulti (brexpiprazole) for Schizophrenia and Adjunctive Treatment for Major Depressive Disorder
Tokyo, Japan and Valby, Denmark – July 11, 2015 –Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food and Drug Administration (FDA) approved Rex...
Actavis Receives FDA Approval for Viibryd (vilazodone HCl) 20mg Once Daily as a Therapeutic Dose
DUBLIN, March 16, 2015 /PRNewswire/ – Actavis plc (NYSE: ACT) today announced the U.S. Food and Drug Administration (FDA) has approved a lower therapeutic dose of Viibryd (vilazodone HCl) (20mg) to...
FDA Medwatch Alert: Effexor XR 150 Mg Extended-Release Capsules (Pfizer) and Venlafaxine HCl 150 Mg Extended-Release Capsules (Greenstone): Recall - Possible Presence of Tikosyn Capsules
[Posted 03/07/2014] ISSUE: Pfizer Inc. issued a voluntary recall of one lot of 30-count Effexor XR (venlafaxine HCl) 150 mg extended-release capsules, one lot of 90-count Effexor XR (venlafaxine ...
FDA Medwatch Alert: Adipotrim XT by Deseo Rebajar: Recall - Undeclared Drug Ingredient
ISSUE: Deseo Rebajar Inc., is voluntarily recalling lot #052012 of Adipotrim XT sold directly to individual customers in Fajardo, Caguas and Bayamon and in website www.deseorebajar.com. The FDA...
FDA Approves Brintellix to Treat Major Depressive Disorder
Sept. 30, 2013 – The U.S. Food and Drug Administration today approved Brintellix (vortioxetine) to treat adults with major depressive disorder. Major depressive disorder (MDD), commonly referred to...
Forest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of Fetzima for the Treatment of Major Depressive Disorder in Adults
NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that Fetzima (levomilnacipran extended-release capsules), a once-daily serotonin...
FDA Approves Khedezla for Major Depressive Disorder
July 10, 2013 – The United States Food and Drug Administration today approved Khedezla (desvenlafaxine) extended-release tablets for the treatment of major depressive disorder. Khedezla contains the...
Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression
Marlborough, Mass., June 28, 2013 – Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for the use of Latuda (lurasidone HCl) a...
FDA Medwatch Alert: Celexa (citalopram hydrobromide) - Drug Safety Communication: Revised Recommendations, Potential Risk of Abnormal Heart Rhythms
ISSUE: FDA is clarifying dosing and warning recommendations for the antidepressant Celexa (citalopram hydrobromide; also available in generic form). In August 2011, FDA issued a Drug Safety ...
FDA Approves Viibryd to Treat Major Depressive Disorder
ROCKVILLE, Md., Jan. 21, 2011--The U.S. Food and Drug Administration today approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults. Major depressive...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Major Depressive Disorder, Dysthymia, Sexual Dysfunction, SSRI Induced, Seasonal Affective Disorder, Postpartum Depression
Related drug support groups
Lexapro, tramadol, Zoloft, sertraline, Wellbutrin, Cymbalta, trazodone, Prozac, Effexor, view more... citalopram, escitalopram, bupropion, mirtazapine, Abilify, amitriptyline, Celexa, venlafaxine, fluoxetine, Paxil, alprazolam, Effexor XR, Pristiq, lithium, Wellbutrin XL, Viibryd, duloxetine, lamotrigine, quetiapine, Remeron, nortriptyline, Wellbutrin SR, methylphenidate, paroxetine, olanzapine, risperidone, Zyprexa, modafinil, aripiprazole, Elavil, Rexulti, clomipramine, doxepin, Seroquel XR, ketamine, valerian, fluvoxamine, niacin, desvenlafaxine